Selection of phage-displayed anti-guinea pig C5 or C5a antibodies and their application in xenotransplantation

Molecular Immunology

Volumn 36, Issue 18, 1999, Pages 1235-1247

  Link, Claudia ^a   Hawlisch, Heiko ^a   Meyer Zu Vilsendorf, Andreas ^b   Gylerüz, Selim ^a   Nagel, Eckhard ^b   Köhl, Jörg ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NONE

Author keywords

Complement factor C5; Complement factor C5a; Guinea pig; Phage display; Xenotransplantation

Indexed keywords

COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR; CONTROLLED STUDY; GUINEA PIG; LIVER TRANSPLANTATION; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEQUENCE ANALYSIS; XENOTRANSPLANTATION;

ACUTE DISEASE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODY AFFINITY; COMPLEMENT ACTIVATION; COMPLEMENT C5; COMPLEMENT C5A; COMPLEMENT INACTIVATOR PROTEINS; CROSS REACTIONS; GRAFT REJECTION; GUINEA PIGS; HEART TRANSPLANTATION; IMMUNIZATION; LIVER TRANSPLANTATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; RATS; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0033494479     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)00135-2     Document Type: Article

References (47)

1. Åkerström B., Björck L. Protein L: an immunoglobulin light chain-binding bacterial protein. Characterization of binding and physicochemical properties. J. Biol. Chem. 264:1989;19,740-19,746.
2. Åkerström B., Nilson B.H., Hoogenboom H.R., Björck L. On the interaction between single chain Fv antibodies and bacterial immunoglobulin-binding proteins. J. Immunol. Methods. 177:1994;151-163.
3. Ames R.S., Tornetta M.A., Jones C.S., Tsui P. Isolation of neutralizing anti-C5a monoclonal antibodies from a filamentous phage monovalent Fab display library. J. Immunol. 152:1994;4572-4581.
4. Auchincloss H.J., Sachs D.H. Xenogeneic transplantation. Annu. Rev. Immunol. 16:1998;433-470.
5. Barrett R.W., Cwirla S.E., Ackerman M.S., Olson A.M., Peters E.A., Dower W.J. Selective enrichment and characterization of high affinity ligands from collections of random peptides on filamentous phage. Anal. Biochem. 204:1992;357-364.
6. Bitter-Suermann D., Burger R. Guinea pigs deficient in C2, C4, C3 or the C3a receptor. Prog. Allergy. 39:1986;134-158.
7. Bitter-Suermann D., Köhl J. Komplementsystem. Gemsa D., Kalden J.R., Resch K. Immunologie. 1997;70-86 Georg Thieme Verlag, Stuttgart, Germany.
8. Candinas D., Lesnikoski B.A., Robson S.C., Scesney S.M., Otsu I., Myiatake T., et al. Soluble complement receptor type 1 and cobra venom factor in discordant xenotransplantation. Transplant. Proc. 28:1996;581.
9. Celli S., Valdivia L.A., Kelly R.H., Sun H., Tsugita M., Pan F., et al. Mechanisms of protection from humoral rejection by a xenografted liver. Transplant. Proc. 27:1995;300-302.
10. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
11. Clackson T., Hoogenboom H.R., Griffiths A.D., Winter G. Making antibody fragments using phage display libraries. Nature. 352:1991;624-628.
12. Crameri A., Cwirla S., Stemmer W.P. Construction and evolution of antibody-phage libraries by DNA shuffling. Nat. Med. 2:1996;100-102.
13. Dalmasso A.P. The complement system in xenotransplantation. Immunopharmacology. 24:1992;149-160.
14. Dower W.J., Miller J.F., Ragsdale C.W. High efficiency transformation of E. coli by high voltage electroporation. Nucl. Acids Res. 16:(13):1988;6127-6145.
15. Ember J.A., Jagels M.A., Hugli T.E. Characterization of complement anaphylatoxins and their biological responses. Volanakis J.E., Frank M.M. The Human Complement System in Health and Disease. 1998;241-284 Marcel Dekker, New York.
16. Evans M.J., Rollins S.A., Wolff D.W., Rother R.P., Norin A.J., Therrien D.M., et al. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol. Immunol. 32:1995;1183-1195.
17. Hancock W.W., Miyatake T., Koyamada N., Kut J.P., Soares M., Russell M.E., et al. Effects of leflunomide and deoxyspergualin in the guinea pig→rat cardiac model of delayed xenograft rejection: suppression of B cell and C-C chemokine responses but not induction of macrophage lectin. Transplantation. 64:1997;696-704.
18. Hawkins R.E., Russell S.J., Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 226:1992;889-896.
19. Hawlisch H., Frank R., Hennecke M., Baensch M., Sohns B., Arseniev L., et al. Site-directed C3a receptor antibodies from phage display libraries. J. Immunol. 160:1998;2947-2958.
20. Hoogenboom H.R., de Bruine A.P., Hufton S.E., Hoet R.M., Arends J.W., Roovers R.C. Antibody phage display technology and its applications. Immunotechnology. 4:1998;1-20.
21. Irving R.A., Kortt A.A., Hudson P.J. Affinity maturation of recombinant antibodies using E. coli mutator cells. Immunotechnology. 2:1996;127-143.
22. Kabat E.A., Wu T.T., Perry H.M., Gottesmann K.S., Foeller C. Sequences of proteins of immunological interest. 5th ed. 1991;National Institute of Health, Bethesda.
23. Kipriyanov S.M., Dubel S., Breitling F., Kontermann R.E., Heymann S., Little M. Bacterial expression and refolding of single-chain Fv fragments with C- terminal cysteines. Cell Biophys. 26:1995;187-204.
24. Köhl J. The Anaphylatoxins. Dodds A.W., Sim R.B. Complement: A Practical Approach. 1997;135-163 Oxford University Press, Oxford.
25. Köhl J., Bitter-Suermann D. Anaphylatoxins. Whaley K., Loos M., Weiler J.M. Complement in Health and Disease. 1993;299-324 Kluwer Academic Publishers, Dordrecht.
26. Kretzschmar T., Aoustin L., Zingel O., Marangi M., Vonach B., Towbin H., Geiser M. High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies. J. Immunol. Methods. 195:1996;93-101.
27. Kroshus T.J., Rollins S.A., Dalmasso A.P., Elliott E.A., Matis L.A., Squinto S.P., Bolman R.M. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation. 60:1995;1194-1202.
28. Leventhal J.R., Matas A.J., Sun L.H., Reif S., Bolman R.M., Dalmasso A.P., Platt J.L. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model. Transplantation. 56:1993;1-8.
29. Low N.M., Holliger P.H., Winter G. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. 260:1996;359-368.
30. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:1991;581-597.
31. Matis L.A., Rollins S.A. Complement-specific antibodies: designing novel anti-inflammatories. Nat. Med. 1:1995;839-842.
32. McCafferty J., Fitzgerald K.J., Earnshaw J., Chiswell D.J., Link J., Smith R., Kenten J. Selection and rapid purification of murine antibody fragments that bind a transition-state analog by phage display. Appl. Biochem. Biotechnol. 47:1994;157-171.
33. Miki T., Goller A., Rao A, Wang X., Yin W.Y., Tandin A., et al. Tacrolimus enhances the immunosuppressive effect of cyclophosphamide but not that of leflunomide or mycophenolate mofetil in a model of discordant liver xenotransplantation. Transplant. Proc. 30:1998;1091-1092.
34. Miyagawa S., Hirose H., Shirakura R., Nakata S., Naka Y., Kitagawa S., et al. The mechanism of discordant xenograft rejection. Transplant. Proc. 21:1989;520-521.
35. Mohr M., Hopken U., Oppermann M., Mathes C., Goldmann K., Siever S., et al. Effects of anti-C5a monoclonal antibodies on oxygen use in a porcine model of severe sepsis. Eur. J. Clin. Invest. 28:1998;227-234.
36. Nilson B.H., Solomon A., Björck L., Åkerström B. Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. J. Biol. Chem. 267:1992;2234-2239.
37. Ono K., Lindsey E.S. Improved technique of heart transplantation in rats. J. Thorac. Cardiovasc. Surg. 57:1969;225-229.
38. Rainard P., Sarradin P., Paape M.J., Poutrel B. Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk. Vet. Res. 29:1998;73-88.
39. Rollins S.A., Matis L.A., Springhorn J.P., Setter E., Wolff D.W. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Transplantation. 60:1995;1284-1292.
40. Saadi S., Platt J.L. Immunology of xenotransplantation. Life Sci. 62:1998;365-387.
41. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Habor, NY.
42. Thomas T.C., Rollins S.A., Rother R.P., Giannoni M.A., Hartman S.L., Elliott E.A., et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33:1996;1389-1401.
43. Vakeva A.P., Agah A., Rollins S.A., Matis L.A., Li L., Stahl G.L. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 97:1998;2259-2267.
44. Wang Y., Hu Q., Madri J.A., Rollins S.A., Chodera A., Matis L.A. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. USA. 93:1996;8563-8568.
45. Whaley K., North J. Haemolytic assays for whole complement activity and individual components. Dodds A.W., Sim R.B. Complement: A Practical Approach. 1997;Oxford University Press.
46. Winter G., Griffiths A.D., Hawkins R.E., Hoogenboom H.R. Making antibodies by phage display technology. Annu. Rev. Immunol. 12:1994;433-455.
47. Yang W.P., Green K., Pinz-Sweeney S., Briones A.T., Burton D.R., Barbas C.F. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254:1995;392-403.